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Introduction
Following the widespread application of standard endovas-
cular aneurysm repair (EVAR), endovascular techniques 
have evolved to address more complex aortic pathologies. 
The use of fenestrated endovascular aneurysm repair 
(FEVAR) was introduced in 1999.1 Improvements in tech-
nology have enabled treatment of juxtarenal abdominal 
(JAA), suprarenal abdominal (SAA), and thoracoabdomi-
nal (TAAA) aneurysms. The efficacy of FEVAR in the 
treatment of JAA and SAA has been demonstrated in sev-
eral reports.2–4 FEVAR is associated with low operative 
mortality, comparing favorably to open surgery in terms of 
morbidity, and seems to constitute a valid treatment option 
in both low- and high-risk patients.5
The concept of fenestrations and scallops in the graft 
fabric is to extend the sealing zone of the aortic stent-graft 
to a healthy segment of the aorta at the level of the renal or 
visceral arteries. The initial assumption was that with a 
higher number of fenestrations, the complexity and poten-
tial pitfalls of the procedure would rise significantly. With 
time, the expansion of the technique, as well as increasing 
operator experience, have led to the use of more complex 
devices with an increasing number of fenestrations incorpo-
rated in the stent-graft.3
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Abstract
Purpose: To report the outcomes of fenestrated endovascular aneurysm repair (FEVAR) and compare early and midterm 
results in relation to stent-graft complexity. Methods: Between August 2006 and December 2014, 141 consecutive 
patients (mean age 72±7.6 years, range 50–89; 120 men) were treated electively with FEVAR for short-neck, juxtarenal, or 
suprarenal aortic aneurysms. Forty-five patients treated with stent-grafts featuring renal-only fenestrations were assigned 
to group A, while 96 patients receiving additional fenestrations for the superior mesenteric and/or celiac arteries were 
assigned to group B. Technical success, operative mortality and morbidity, target vessel patency, endoleak, reintervention, 
and survival were compared between the groups. Survival, target vessel stent patency, and reintervention during follow-
up were estimated by Kaplan-Meier analysis; the estimates are presented with the 95% confidence interval (CI). Results: 
Technical success was achieved in 135 (95.7%) patients. Overall 30-day operative mortality was 3.5% (5/141). Perioperative 
complications occurred in 16 (12.1%) patients. Mean follow-up was 33±23 months. Overall estimated survival was 85.1% 
(95% CI 79.1% to 91.1%) at 1 year and 75.8% (95% CI 68.2% to 83.5%) at 3 years. Freedom from reintervention was 
90.6% (95% CI 85.6% to 95.6%) at 1 year and 79.2% (95% CI 71% to 87.5%) at 3 years. There was no statistically significant 
difference between the groups in terms of perioperative mortality or morbidity, endoleak, survival, target vessel patency, 
or reintervention. Conclusion: The use of FEVAR for juxta- and suprarenal aneurysms is associated with low 30-day 
mortality/morbidity and high midterm efficacy. So far, perioperative and midterm results are not affected by the use of 
more complex fenestrated designs.
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Initially, a few small studies attempted to evaluate the 
influence of stent-graft complexity on the outcome of 
FEVAR.6,7 Recently, 3 larger studies have reported results 
of FEVAR stratified according to landing zone and number 
of fenestrations.2,3,8 Nevertheless, results have been conflict-
ing, and the impact of the proximal landing zone on FEVAR 
outcome still remains unclear.2,3,8,9 These discrepancies are 
enhanced by the lack of common reporting standards.
This study aims to evaluate early and midterm results of 
FEVAR in the treatment of abdominal aortic aneurysms 
(AAAs), comparing patients treated with fenestrated 
devices featuring renal-only fenestrations (RAs) and a scal-
lop for the superior mesenteric artery (SMA) with patients 
requiring additional fenestrations for the SMA and the 
celiac artery (CA).
Methods
Between August 2006 and December 2014, 141 consecutive 
patients (mean age 72±7.6 years, range 50–89; 120 men) 
were electively treated with FEVAR for short-neck, juxtare-
nal, or suprarenal aortic aneurysms. Patients were assigned 
to 2 groups according to the configuration of the fenestrated 
stent-graft. Group A consisted of 45 patients treated with 
stent-grafts featuring renal-only fenestrations; group B 
included 96 patients with additional fenestrations for the 
SMA and/or the CA. The distributions of sex, age, and 
comorbidities in the groups are demonstrated in Table 1. 
Patients with type IV TAAAs requiring additional thoracic 
stent-graft components proximal to the fenestrated stent-
graft were excluded. Patients with previous failed EVAR or 
open abdominal aortic surgery were not excluded. FEVAR 
as a technique was approved by the institution’s ethics 
committee.
Aneurysm morphology was assessed by thin cut (≤1 
mm) computed tomography angiography (CTA) with multi-
planar reconstructions. The physical status of all patients 
was assessed preoperatively with the American Society of 
Anesthesiologists (ASA) score. The main indication for 
FEVAR included a proximal neck outside indications for 
use of infrarenal stent-grafts but otherwise suitable for 
EVAR in an AAA of at least 50 mm in diameter (or <50 mm 
with a perforating ulcer or in conjunction with iliac aneu-
rysm >35 mm in diameter).
Stent-Grafts
Planning of fenestrated stent-grafts has been previously 
described in detail.10,11 Briefly, stent-grafts were most com-
monly customized based on the Cook Zenith platform 
(William A. Cook Australia, Ltd, Brisbane, Australia). In 8 
cases, where the distance between target vessel ostia was 
prohibitive for a fenestrated Cook stent-graft, a custom-
made fenestrated Anaconda stent-graft (Vascutek Terumo, 
Inchinnan, Scotland) was applied. Fenestrations and scal-
lops for the visceral vessels were fitted according to preop-
erative CTA measurements. The most common configuration 
consisted of a composite 3-part system with a proximal 
fenestrated tube, a distal bifurcated component, and a con-
tralateral limb. In some cases of limited working length dis-
tally (eg, failed previous bifurcated surgical graft or EVAR), 
a fenestrated cuff only was used. Proximal and distal sealing 
zones ≥20 mm in length were always planned. In cases of 
common iliac artery aneurysm ≥35 mm in diameter, an iliac 
branched device (William A. Cook Australia) was applied.
Target vessels were routinely secured with a balloon-
expandable Atrium Advanta V12 stent-graft (Atrium 
Maquet Getinge Group, Mijdrecht, the Netherlands). In 
cases of severe angulation, an additional self-expanding 
stent was applied [Zilver (William A. Cook Australia) or 
LifeStent (Bard PV, Tempe, AZ, USA)].
Procedure
The procedures were initially carried out in an operating 
room with a mobile C-arm (OEC 9900 Elite; General 
Electric Healthcare, Milwaukee, WI, USA); since January 
2012, procedures were conducted in a hybrid operating 
room with fixed imaging (Allura Xper FD20; Philips 
Medical Systems, Best, the Netherlands). The operation 
was always done under general anesthesia, with surgical 
access via bilateral femoral cutdowns. The main operative 
technique has been described in detail previously.4,11 
Table 1. Patient Characteristics and Procedure Data.a
Variable Group A (n=45) Group B (n=96) p
Age, y 72.3±7.2 71.8±7.7 0.57
Men 37 83 0.61
Aneurysm diameter, mm 59.4±9.8 58.4±10.2 0.50
Smoking (current or past) 36 (80.0) 80 (83.3) 0.64
Hypertension 41 (91.1) 93 (96.9) 0.21
Diabetes mellitus 7 (15.6) 25 (26.0) 0.19
Hypercholesterolemia 28 (62.2) 63 (65.6) 0.71
CAD 36 (80.0) 63 (65.6) 0.11
COPD 28 (62.2) 45 (46.9) 0.11
GFR, <60 mL/min/1.73 m2 15 (33.3) 43 (44.8) 0.19
GFR, mL/min/1.73 m2 62.7±17.2 59.4±19.1 0.27
Previous aortic surgery 7 (15.6) 29 (30.2) 0.07
ASA ≥III 32 (71.1) 64 (66.7) 0.70
Procedure time, min 256±119 273±99 0.57
Fluoroscopy time, min 40 (10–150) 50 (20–160) 0.01
Contrast agent, mL 245 (105–361) 210 (75–450) 0.21
ICU stay, d 2 (0–12) 3 (0–55) 0.01
Hospital stay, d 12 (5–60) 14 (2–90) 0.10
Abbreviations: ASA, American Society of Anesthesiologists; CAD, coronary artery 
disease; COPD, chronic obstructive pulmonary disease; GFR, glomerular filtration 
rate; ICU, intensive care unit; PAD, peripheral artery disease.
aContinuous data are presented as the means ± standard deviation or medians 
(range); categorical data are given as the counts (percentage).
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Heparinization was applied to maintain an activated clot-
ting time ≥300 seconds. Intraoperative limb perfusion was 
monitored with a cerebral/somatic oxymetry system 
(INVOS; Medtronic, Minneapolis, MN, USA).
Cerebrospinal fluid (CSF) drainage for paraplegia pre-
vention was applied in patients treated with stent-grafts fea-
turing 4 fenestrations and in selected patients receiving 3 
fenestrations who had prominent lumbar arteries in the 
intended proximal landing zone. The spinal catheter was 
inserted before intubation. Spinal fluid pressure was initially 
measured with a manometer equipped with a 3-way stop 
cock; beginning in 2011, pressure was monitored in a closed, 
pressure-controlled system (Liquo Gard; Möller Medical 
GmbH, Fulda, Germany) at a baseline of 12 cm H2O. In such 
cases, the patient was postoperatively transferred to the 
intensive care unit (ICU), and systolic blood pressure was 
kept ≥80 mm Hg to increase perfusion of the spine through 
collateral circulation. In case of spinal cord ischemia (SCI), 
mean arterial pressure was adjusted to ≥90 mm Hg, and CSF 
pressure was set at ≤10 cm H2O.
Technical success was defined as successful deployment 
of the planned stent-grafts with patent stented target vessels 
and absence of type I or III endoleak at the first postopera-
tive CTA.
Postoperative Management
Patients were monitored with clinical and laboratory exami-
nation, CTA, and plain abdominal radiography in anteropos-
terior, lateral, and oblique projections prior to discharge. 
Further follow-up consisted of CTA at 1 month, 1 year, and 
annually thereafter, depending on each patient’s characteris-
tics. Patients were additionally monitored with ultrasonogra-
phy at 6-month intervals by an experienced sonographer 
using a high-resolution ultrasound machine and a 5/1-MHz 
convex probe. Modalities applied included duplex, power 
Doppler with contrast enhancement, and contrast harmonic 
imaging with a low mechanical index (<0.2). SonoVue 
(Bracco, Milan, Italy) was administered to each patient 
intravenously as a 2.4-mL bolus injection. If the 1-year CTA, 
duplex ultrasound, and renal function were within normal 
limits, the need for further yearly CTAs was discussed in 
group with the intent to reduce the number of CTAs. If there 
was suspicion of endoleak or branch vessel malperfusion, 
digital subtraction angiography was carried out for further 
evaluation and possible reintervention.
Data Analysis
Variables are presented as mean ± standard deviation in 
case of normal distribution and median plus range in case of 
skewed distribution. Analyzed outcomes included technical 
success, operative time, contrast agent volume, early mor-
tality and major morbidity, and late events with regard to 
target vessel stent patency, endoleak, reintervention, and 
death. Major morbidity was defined as the occurrence of 
clinically relevant pulmonary, cardiac, or gastrointestinal 
complications, postoperative deterioration of the glomeru-
lar filtration rate >30%, paraplegia/paraparesis, and local 
complications requiring surgical treatment.
The chi-square test was applied to compare categorical 
variables, while continuous data were compared using the 
Mann-Whitney-Wilcoxon test. Survival, target vessel stent 
patency, and reintervention during follow-up were sub-
jected to Kaplan-Meier analysis and compared using the 
log-rank test; estimates are presented with the 95% confi-
dence interval (CI). Statistical significance was set at 
p<0.05. Statistical analyses were performed using SPSS for 
Windows (version 20.0; IBM Corporation, Somers, NY, 
USA) and MedCalc (MedCalc Software, Ostend, Belgium).
Results
In total, 403 vessels were targeted with fenestrations (278 
RAs, 96 SMAs, 29 CAs) and 110 vessels were targeted with 
scallops (3 RAs, 40 SMAs, 67 CAs). Preoperative charac-
teristics examined were similar between the 2 groups. There 
was a higher tendency for previous aortic surgery in group 
B, but this did not reach statistical significance (p=0.07). In 
total, 36 patients had had previous aortic surgery. Thirteen 
patients were treated due to failed open abdominal aortic 
surgery and another 23 patients due to failed EVAR.
Operative Data and Technical Success
Mean operative time was 268±105 minutes (range 100–
648), median fluoroscopy time was 45 minutes (range 10–
160), and median contrast volume was 220 mL (range 
75–450). There was no statistically significant difference 
between the groups in operative time (p=0.16) or contrast 
volume used (p=0.21), whereas fluoroscopy time was sig-
nificantly longer in group B (p=0.01). Operative data are 
displayed in Table 1.
Technical success was achieved in 135 (95.7%) patients. 
In group A, 44 (97.7%) of the 45 patients has a successful 
procedure; 1 case was converted to open surgery as a result 
of failure to catheterize a very calcified and tortuous right 
RA. In the 96 group B patients, technical success was 
achieved in 91 (94.7%). One patient had heavily calcified 
iliac arteries bilaterally, and the stent-graft could not be 
introduced despite the use of an additional through-and-
through wire via an axillary access. Multiple attempts to 
advance the stent-graft ultimately resulted in deformation 
and partial unsheathing of the graft in the iliac artery. The 
stent-graft was removed and the case converted. Another 
patient with a stenotic CA experienced an intraoperative 
dissection of the SMA, which occluded collateral circula-
tion to the CA. The patient developed liver ischemia on the 
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first postoperative day and was treated with iliac hepatic 
bypass, but ultimately died. Catheterization of the right RA 
was not possible in 2 patients. In the first, who had a hypo-
plastic renal artery for the right kidney, the fenestration was 
positioned too high, and the vessel was left unstented. This 
led to early occlusion that did not affect the patient’s renal 
function. In the second patient, an angulated right RA could 
not be catheterized from above or below, and an iliorenal 
bypass was carried out. In the last patient, catheterization of 
the CA was not possible, and the vessel was overstented 
with a proximal cuff. There was no statistically significant 
difference regarding technical success between the 2 groups 
(p=0.66).
Perioperative Mortality/Morbidity
Five (3.5%) patients died in the perioperative period. In 
group A, the 30-day operative mortality was 6.6% (3/45). 
One patient died due to mesenteric ischemia on the seventh 
postoperative day despite having a patent SMA and CA, 
most likely due to multiple visceral embolizations. One 
patient died on the third postoperative day after suffering 
multiple thromboses of both lower limbs and the intestinal 
arteries. Finally, the third patient had been treated with an 
aortouni-iliac stent-graft and a crossover femorofemoral 
bypass due to a heavily calcified left iliac artery. The bypass 
graft became infected, with erosive bleeding. It was replaced 
with a homograft, but the patient died due to cardiac com-
plications at 30 days.
Operative mortality was 2.1% (2/96) in group B. The 
patient with SMA dissection described previously died due 
to liver ischemia on the second postoperative day. The sec-
ond patient succumbed to multiple organ failure on the sev-
enth postoperative day as a result of microembolization 
despite the fact that all targets vessels were patent. There 
was no statistically significant difference regarding periop-
erative mortality between the 2 groups (p=0.32).
Perioperative complications occurred in 16 (12.1%) 
patients, 3 (6.7%) were in the 45 group A patients. One 
patient suffered postoperative pneumonia but recovered 
completely. Two patients had surgical access problems that 
required surgical debridement. In the 14 (14.5%) of 96 
group B patients, SCI occurred in 4 treated with stent-grafts 
featuring 4 fenestrations. The first patient was under CSF 
drainage, suffered temporary paresis of one lower limb, and 
recovered completely following adjustment of mean arterial 
pressure to ≥90 mmHg and drainage increase. The second 
patient developed paraparesis following probe clamping of 
the spinal catheter on the second postoperative day and 
recovered completely after reopening the spinal catheter. 
The spinal catheter was ultimately removed on the fifth 
postoperative day, following renewed probe clamping with-
out SCI symptoms. The remaining 2 patients had preopera-
tively declined CSF drainage. Both patients suffered SCI 
with paresis of one lower limb, which resolved completely 
after placement of a spinal catheter.
Renal function deterioration occurred in 3 patients with 
known renal insufficiency. All patients had patent renal 
arteries. Two of these patients required temporary dialysis. 
In all cases, renal function recovered within 30% of the 
baseline value. Three patients developed ischemia of the sig-
moid colon, which was treated with sigmoidectomy. One 
patient suffered a cerebral infarction with amaurosis and was 
treated successfully with lysis. One patient developed post-
operative pancreatitis. Postoperative pneumonia occurred in 
1 patient. Finally, the last patient developed a groin infection 
that required surgical debridement. There was no statisti-
cally significant difference between the 2 groups (p=0.27) in 
terms of morbidity.
Median hospital stay was 13 days (range 3–90) and 
median ICU stay was 2 days (range 0–55). Hospital stay did 
not significantly differ between the 2 groups (p=0.1), but 
group B patients had a significantly longer ICU stay 
(p=0.01).
Follow-up
Mean follow-up was 33±23 months and was slightly longer 
in group A (40±29 months) than in group B (30±19 months; 
p=0.07). Of the 34 deaths in follow-up, 3 were aneurysm-
related (2 group A and 1 group B). In group A, the first 
patient died due to aneurysm rupture as a result of a type Ia 
endoleak. This patient had undergone banding of the proxi-
mal neck at 10 months postoperatively. The endoleak per-
sisted but no further surgical measures were undertaken 
because the patient had in the meantime been diagnosed 
with renal cell carcinoma and lung metastasis. The second 
patient had a large aneurysm with persistent type II endoleak 
from the inferior mesenteric artery (IMA) and lumbar arter-
ies. Laparoscopic clipping of the IMA was undertaken at 6 
months. The endoleak persisted, and the aneurysm grew 
from 68 to 75 mm. A laparotomy with aortotomy and lum-
bar artery suture was carried out at 44 months. The patient 
died as a result of cardiac complications following the 
procedure.
In group B, 1 patient developed an aortoduodenal fistula 
at 3 months. This patient had been treated for rapid expan-
sion of a juxtarenal aneurysm after failed standard EVAR 
with signs of infection. The fenestrated stent-graft was 
partly replaced with an antimicrobial silver-coated graft; 
the patient had a prolonged hospital stay and ultimately died 
due to multiple organ failure at 5 months postoperatively. 
Overall estimated survival was 85.1% (95% CI 79.1% to 
91.1%) at 1 year and 75.8% (95% CI 68.2% to 83.5%) at 3 
years. For group A, overall survival estimates at 1 and 3 
years were 88.4% (95% CI 78.9% to 97.9%) and 75.6% 
(95% CI 61.6% to 89.6%); for group B, the estimates were 
83.6% (95% CI 76.0% to 91.2%) and 76.3% (95% CI 67.5% 
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to 85.2%), respectively (p=0.96). Cumulative survival is 
demonstrated in Figure 1A.
Eight target vessels occluded in follow-up, 5 left RA, 1 
right RA, and both renal arteries in 1 patient. In 5 patients, 
the reason for the occlusion was adverse anatomy (3 narrow 
RAs with early bifurcation and 1 small accessory RA). In 1 
patient, the left RA developed a pseudoaneurysm at the end 
of the Advanta V12 stent-graft. An unsuccessful attempt 
was undertaken to extend the stent-graft deeper into the RA, 
but the vessel ultimately occluded. In 1 patient, the left RA 
occluded following gastrointestinal bleeding with hypoten-
sion. Finally, in the last patient the RA occluded in the con-
text of B-cell acute lymphoblastic leukemia. Renal function 
did not deteriorate in 4 of 7 patients with RA occlusion. In 
2 patients, renal function deterioration >30% was noted, 
without the need for dialysis. The patient with bilateral RA 
occlusion presented in the emergency department after 1 
week of ongoing pain; a recanalization attempt was unsuc-
cessful, and the patient became dialysis dependent. Target 
vessel patency estimates at 1 and 3 years were 97.2% (95% 
CI 94% to 100%) for group A and 98.9% (95% CI 97.8% to 
100%) for group B, respectively (p=0.11).
Unplanned reinterventions were required in 26 (18.4%) 
patients during follow-up. The reasons for reintervention 
and reintervention time are listed in Table 2. Eleven (24.4%) 
of the 45 group A patients required reintervention. In 3, the 
reason was stenosis of a target vessel. In another 3, reinter-
vention was required due to persistent type II endoleak with 
aneurysm progression. Of the remaining 5 patients, 2 were 
treated for a type Ia endoleak, 1 for bilateral RA occlusion, 
1 for the previously mentioned RA pseudoaneurysm, and 1 
for a type III endoleak from the left iliac limb.
In group B, 15 (15.6%) of the 96 patients underwent a 
reintervention. Five patients were treated for stenosis of a 
target vessel and 4 for type II endoleak. In 2 patients, an 
Figure 1. Kaplan-Meier graphs of (A) cumulative overall patient 
survival and (B) freedom from reintervention in groups A and B.
Table 2. Cases Requiring Reintervention.
Group Reason
Lapsed 
Time, mo Procedure
A RRA/LRA occlusions 1 Failed
RRA/LRA stenosis 13 BE stent-graft
RRA stenosis 36 BE stent-graft
SMA/CA stenoses 72 BE stent-graft
LRA pseudoaneurysm 43 Failed
Type II EL (lumbar) 3 CE + Onyx injection
Type II EL (IMA) 6; 44 Laparoscopic clipping; 
laparotomy
Type II EL (lumbar) 60 CE + Onyx injection
Type Ia EL 10 Proximal banding
Type Ia EL 18 4× FEVAR
Type III EL 3 Limb relining
B SMA stenosis 6 BE stent-graft
LRA/RRA stenoses 14 DEB angioplasty
LRA stenosis 16 DEB angioplasty
SMA stenosis 17 BE stent-graft
CA stenosis 20 BE stent-graft
Type II EL (IMA) + 
SMA stenosis
4; 8 Laparoscopic clipping; 
BE stent-graft
Type Ib EL (iliac) + 
RRA/SMA stenoses
5; 16 IBD right IIA; BE 
stent-graft
Type II EL (IMA + 
lumbar)
1; 16 Laparoscopic clipping; 
laparotomy
Type II EL (IMA) 5 Laparoscopic clipping
Type II EL (IMA) 21 CE
Type II EL (IMA + 
lumbar)
24; 30 Laparoscopic clipping; 
laparotomy
Type Ib EL (CA) 32 BE stent-graft
Type III EL (NA) 1 Bridging BE stent-graft
Access problem 
(SMA)
1 Transbrachial BE 
stent-graft
Aortoduodenal fistula 3 Conversion
Abbreviations: BE, balloon-expandable; CA, celiac artery; CE, coil embolization; 
DEB, drug-eluting balloon; EL, endoleak; FEVAR, fenestrated endovascular 
aneurysm repair; IBD, iliac branched device; IMA, inferior mesenteric artery; LRA, 
left renal artery; RRA, right renal artery; SMA, superior mesenteric artery.
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initial reintervention was required due to a type II and a type 
Ib endoleak, respectively, that was later followed by a sec-
ond reintervention due to target vessel stenosis. Of the 
remaining 4 patients, 1 was treated for a type Ib endoleak 
from the CA and another for dislocation of the RA stent-
graft and type III endoleak. In a patient in whom the CA 
could not be catheterized from the groin and the respective 
fenestration was left unstented, the fenestration was stented 
2 weeks postoperatively via a brachial access. The final 
reintervention was in the patient who developed aortoduo-
denal fistula and had to be converted. Overall freedom from 
reintervention was 90.6% (95% CI 85.6% to 95.6%) at 1 
year and 79.2% (95% CI 71% to 87.5%) at 3 years. The 
estimates were 89.8% (95% CI 80.2% to 99.4%) and 79.7% 
(95% CI 66% to 93.4%), respectively, in group A and 91.0% 
(95% CI 85% to 97%) and 79.1% (95% CI 69.2% to 89%), 
respectively (p=0.76), in group B. Estimated freedom from 
reintervention is demonstrated in Figure 1B.
Endoleaks were detected during follow-up in 25 (17.7%) 
patients. In group A, 6 (13.3%) patients had endoleaks (3 
type II, 2 type Ia endoleak, and 1 type III) and were all 
treated. In group B, 19 (19.7%) patients had endoleaks (16 
type II, 2 type Ib, and 1 type III). Reintervention was required 
in 8 of these patients. The type II endoleaks in 11 patients 
were not associated with aneurysm progression and were 
treated conservatively. There was no statistically significant 
difference in endoleaks between the 2 groups (p=0.47).
Discussion
FEVAR is a well-established technique for the treatment of 
complex AAs, with numerous reports showing good early 
results and midterm durability.2,12,13 As interventionists 
have become more confident with the use of complex endo-
vascular techniques, increasingly challenging pathologies 
are now being treated with FEVAR. It is therefore important 
to stratify results according to aortic anatomy and technical 
complexities.
Several reports have compared FEVAR results with 
regard to stent-graft complexity.2,3,6–9 Results have been 
inconsistent, partly due to the differences in reporting stan-
dards. Some authors include type IV TAAAs in the statisti-
cal analysis as well as patients treated with branched 
stent-grafts.2,8 Furthermore, there is a lack of consensus 
regarding how to classify JAAs and SAAs and the subse-
quent extent of repair. Result stratification has been carried 
out according to several different standards, with other 
authors comparing renal-only fenestrations to more complex 
designs, while others apply the aneurysm zone classification 
or the Society for Vascular Surgery/American Association 
for Vascular Surgery anatomical severity score.7–9
It is our belief that stratification of FEVAR results in the 
abdominal aorta should be limited to abdominal aortic 
pathology. The current series compared solely patients with 
JAAs and SAAs excluding patients with TAAAs. The use 
of branches is generally associated with thoracoabdominal 
pathology, so patients treated with branched stent-grafts, 
which require a significantly more complex procedure 
using an additional axillary access, were also excluded from 
the study.
The classification of patients in this study (renal only 
fenestrations and a SMA scallop vs additional SMA or CA 
fenestrations) reflects procedural complexity in relation to 
the number and position of the vessels that require catheter-
ization. As more fenestrations are added, additional cathe-
terizations and wire manipulations are required, which 
increases the risk of vessel dissection. High-quality lateral 
imaging for the SMA and CA is required, especially in 
obese patients, which in return makes such procedures in 
nonhybrid operating rooms problematic. More lumbar 
arteries are overstented, which increases the risk of SCI 
and, in our view, necessitates the use of CSF drainage. 
There was no differentiation between zone 7 and zone 8 
aneurysms since our procedures occasionally feature an 
additional fenestration for the CA but leave that fenestration 
unstented as opposed to using a proximal CA scallop.
Baseline demographics were balanced between the 2 
groups, and technical success did not differ significantly. 
Overall 30-day mortality in this series was similar to a 
recent review from Di et al,12 in which a 2.52% pooled esti-
mate for 30-day mortality was reported. While 30-day mor-
tality did not differ significantly between the 2 groups, 
group B patients had a nonsignificant higher rate of periop-
erative complications. It has to be noted that 4 group B 
patients developed temporary SCI, which is in accord with 
a recent report from Mastracci et al,2 associating the length 
of graft coverage to SCI. In all 4 cases, symptoms regressed 
following CSF drainage, highlighting its importance for 
SCI prevention and treatment. Insertion of the spinal cath-
eter was also likely the reason patients in group B had a 
longer mean ICU stay.
Estimated survival and target vessel patency rates were 
high in both groups, confirming the midterm efficacy of 
FEVAR reported in other studies.2–4 Notably, 2 group A 
patients had proximal type I endoleaks as opposed to zero in 
group B. One of these endoleaks resulted in an aneurysm-
related death, whereas in the second case additional treat-
ment with a stent-graft featuring 4 fenestrations was 
necessary. There is an ongoing debate regarding the fate of 
type II endoleaks in EVAR and FEVAR. Although type II 
endoleaks are usually treated conservatively, a persisting 
type II endoleak with ongoing aneurysm progression is in 
our opinion an indication for treatment. First, an attempt is 
made to selectively catheterize the respective vessel for 
angiography and coil embolization of the IMA or lumbar 
arteries. In case of catheterization failure with endoleak 
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persistence and aneurysm growth, laparoscopic clipping of 
the IMA becomes necessary.
The impact of landing zone level on FEVAR outcome is 
an essential question as complex endovascular techniques 
advance and off-the-shelf fenestrated stent-grafts are 
released. The question this article attempts to address is: 
Should fenestrations be limited to the minimum required to 
achieve proximal seal or is it wiser to have a low threshold 
when deciding to increase the coverage of the visceral 
aorta to ensure the durability of the repair? This study indi-
cates that there appears to be no increased risk to including 
suprarenal fenestrations when treating abdominal aortic 
pathology, with the benefit of an improved perirenal aortic 
sealing. Although additional fenestrations increase proce-
dural complexity, endovascular specialists should not hesi-
tate to extend the proximal landing zone to or above the CA 
when necessary.
Limitations
The number of patients is too low to support robust statisti-
cal conclusions. Furthermore, these procedures took place 
in a high-volume center with experience in complex endo-
vascular procedures, so the results may not be generalizable 
to less experienced operators/centers.
Conclusion
The use of FEVAR for JAAs and SAAs is associated with 
low 30-day mortality and morbidity and high midterm effi-
cacy. So far, perioperative and midterm results are not 
affected by the use of more complex fenestrated designs 
featuring fenestrations for the SMA and the CA.
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